Thanks for that, IMU could apply now for this, as its my understanding that this expediates the approval process, and should be applied for around phase 2 trials, but is not an approval to market the therapy. Phase 3 trials will still need to happen and these take time. But that said a FDA breakthrough therapy designation could help the share price? and also this designation would indicate that the therapy and need for the therapy are critical to patients.
The CF33, Vaxinia and Oncarlytics Deal, page-179
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.8¢ |
Change
-0.001(1.45%) |
Mkt cap ! $497.7M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.0¢ | 6.7¢ | $1.242M | 18.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1443066 | 6.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.9¢ | 671816 | 6 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
-0.001 ( 0.72 %) |
||||
| Open | High | Low | Volume | ||
| 6.9¢ | 6.9¢ | 6.7¢ | 6493774 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| IMU (ASX) Chart |